Related Experiment Video
Updated: Jun 22, 2026

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment
1Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. buschtm@mail.med.upenn.edu
Abstract:
Photodynamic therapy has been widely replaced by antiangiogenesis agents for the first-line therapy for exudative age-related macular degeneration (AMD). There is a strong basis for predicting that a combination of photodynamic therapy and antiangiogenesis agents may address the relative disadvantages of each. By improving the rates of response, photodynamic therapy has the potential to reduce the frequency with which intravitreal injections of antiangiogenesis agents are required. Antiangiogenesis agents may augment the activity of photodynamic therapy by inhibiting its counterproductive upregulation of vascular endothelial growth factor. Clinical studies of this combination are being advanced in both AMD and in the treatment of malignancies.
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Modified-Release Drug Delivery Systems: Site-Targeted

